SBIR/STTR Research Award

Species Specific Antisera and Positive and Negative Control of

Award identifier 87d671513284e61d6729209712c1a078a2b13652b9b708fff675bbbb25c9ad38Awarding agency Department of Health and Human Services

Award amount

$50,000

Program and phase

SBIR · Phase I

Award year

1993

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
Not reported
Recipient company
ANATRACE, INC.
Proposal award date
Not reported
Contract end date
Not reported
UEI
Not reported
Solicitation number
Not reported
Topic code
Not reported

Research abstract

PRINCIPAL INVESTIGATOR: Garcia, Jorge L. AWARDEE ORGANIZATION: Berkeley Antibody Company 4131 Lakeside Drive, Suite B Richmond, CA 94806-1965 TELEPHONE NUMBER: (510) 222-4940 AWARDEE NUMBER: 200-93-0609 A number of wildlife species are natural reservoirs for zoonotic disease pathogens in the U. S. Many of the serologic tests currently conducted on wildlife species, particularly ELISA, use animal conjugates developed for domestic animals. Data about wildlife species generated with assays using such heterologous reagents can leave questions about the validity of the results. In addition, there are few known positive and negative sera available for the various wildlife species and disease pathogens. The development of a bank of antisera against the important disease reservoir species and known control sera against the significant zoonotic disease in the U. S. would allow public health investigators at CDC, NIH, and USDA state health and animal agencies, and universities to conduct appropriate serologic tests on wildlife species and properly interpret the results. These antisera and sera could also be used for insect blood meal identification. In the Phase I effort, we plan to develop polyclonal antibodies against immunoglobulins and other blood proteins from a variety of wildlife species which potentially harbor various zoonotic diseases. In addition, we will begin to assemble a bank of positive and negative control reagents from the various host species. In Phase II, we will continue to produce polyclonal antibodies but will also expand the program to include production of monoclonal antibodies as well, and will develop controlled assays to monitor for infection of various species with these diseases.

Technology keywords

Not reported

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.